Back to top
more

UnitedHealth Group (UNH)

(Real Time Quote from BATS)

$580.72 USD

580.72
1,270,953

-8.42 (-1.43%)

Updated Sep 17, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 251)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.

Here's Why You Should Retain Boston Scientific (BSX) for Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) strong organic sales and notable acquisitions.

Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays

by Zacks Equity Research

Within Abbott's (ABT) Nutrition arm, while the pediatric nutrition business witnesses a drag, the adult nutrition business continues to perform well.

Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range

by Zacks Equity Research

Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.

Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod

by Zacks Equity Research

Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.

UnitedHealth (UNH) Rewards Shareholders With 13.8% Dividend Hike

by Zacks Equity Research

UnitedHealth's (UNH) strong balance sheet supports its endeavors to return shareholders' funds.

Here's Why Investors Should Retain Alcon (ALC) Stock For Now

by Zacks Equity Research

Investors are optimistic about Alcon's (ALC) better-than-expected results and robust performance across its popular franchises.

Thermo Fisher (TMO) to Promote Mass Spectrometry Imaging

by Zacks Equity Research

Thermo Fisher's (TMO) new deal with TransMIT will advance the use of the AP-SMALDI5 AF ion source with Orbitrap MS technology for spatial multi-omics applications.

PerkinElmer's (PKI) Latest Launch to Expand Food Safety Suite

by Zacks Equity Research

PerkinElmer's (PKI) microbial plates minimize human error by providing standardized protocols and offer a small footprint to save space in incubators and storage areas.

Henry Schein (HSIC) Inks New Deal to Acquire Condor Dental

by Zacks Equity Research

Henry Schein's (HSIC) acquisition of a Switzerland-based dental distribution company will strengthen its presence in the attractive European market.

Bruker (BRKR) to Advance 4D Proteomics With Latest Launch

by Zacks Equity Research

Bruker's (BRKR) timsTOF HT is enhanced for high-throughput, deep and unbiased plasma proteomics, and liquid biopsy biomarker research.

UnitedHealth Group (UNH) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

UnitedHealth Group (UNH) closed the most recent trading day at $497.10, moving +1.41% from the previous trading session.

Here's Why Investors Should Retain Globus Medical (GMED) Now

by Zacks Equity Research

Globus Medical's (GMED) strong international growth and meaningful product launches raise investors' optimism.

Neogen (NEOG) to Offer New Biosecurity Solution in Canada

by Zacks Equity Research

Neogen's (NEOG) newest addition to the biosecurity portfolio is anticipated to curb the spread of diseases like COVID-19 and avian influenza.

Anthem (ANTM) Up 27% in a Year: Can It Retain the Momentum?

by Zacks Equity Research

Anthem (ANTM) is well-poised for growth on sustained top-line improvement, membership increases in Government business and sturdy financial position.

Tandem Diabetes (TNDM) Posts Positive Control-IQ Study Data

by Zacks Equity Research

Data presented at the ADA conference demonstrates Tandem Diabetes' (TNDM) Control-IQ technology's ability to make a positive and sustained impact across a diverse group of people with diabetes.

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on strong sales performance across the U.S. spinal hardware and the U.S. surgical support product lines.

HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.

Insulet (PODD) Reports Pivotal Extended Phase Data for Omnipod 5

by Zacks Equity Research

Insulet's (PODD) Omnipod 5 showed improved time in range and lower HbA1c for pre-school children during an extended phase of the previous pivotal trial.

Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid

by Zacks Equity Research

Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.

Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails

by Zacks Equity Research

Boston Scientific (BSX) is currently looking forward to launching its arterial and venous offerings in the second half of 2022.

Abbott (ABT) FreeStyle Libre 3 System's Study Outcome Favorable

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 3 system is the first and only 14-day CGM system with an overall MARD of 7.9%.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.

LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program

by Zacks Equity Research

LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.

Zacks Industry Outlook Highlights UnitedHealth Group Anthem, Humana, Centene, and Select Medical

by Zacks Equity Research

UnitedHealth Group, Anthem, Humana, Centene, and Select Medical are part of Zacks Industry Outlook article.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on strength across the BSI and BEST businesses.